← All blog posts

Rinvoq (Upadacitinib) and IBD: Patient Questions on JAK Therapy

Posted on August 15, 2026 · Treatment

Content note: Educational content aligned with publicly available patient materials from the Crohn's & Colitis Foundation and other major IBD education sources. Content is used under license from the Foundation for patient education; the Foundation does not endorse IBDPal or MediVue products or services. Last reviewed August 2026. Not individual medical advice.

Educational use only. IBDPal does not provide medical advice, diagnosis, or treatment. Always consult your gastroenterologist or IBD care team for personal decisions.

Rinvoq is an oral JAK inhibitor discussed in IBD clinics. Patients search side effects, labs, and whether pills are safer than infusions. Safety monitoring is part of the therapy, not optional fine print.

What to understand before starting

JAK inhibitors have specific boxed warnings and monitoring frameworks clinicians follow.

Question checklist

Never start or share leftover JAK pills. Prescribing is specialized.

When to seek care promptly

This page cannot diagnose you. Severe bleeding, black tarry stools, fainting, fever with rapid decline, or inability to keep fluids down need urgent evaluation. See when to go to the ER and flare help.

Common myths

Questions for your gastroenterologist

Track patterns in IBDPal and bring a one-week log to visits. Related: immune therapies overview · clot risk · vaccines. Hub: stool and labs decoder.

Read the full interactive version on ibdpal.org.